Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20113215 | 0.81 | KMT2A (0.37) | KMT2AMEN1ATMMAPTALDH1A1 | |
| SCHEMBL464766 | 0.81 | KMT2A (0.37) | KMT2AMEN1ATMMAPTALDH1A1 | |
| SCHEMBL464765 | 0.81 | KMT2A (0.37) | KMT2AMEN1ATMMAPTALDH1A1 | |
| SCHEMBL5312302 | 0.80 | ALDH1A1 (0.49) | KMT2AMEN1ATMMAPTALDH1A1 | |
| SCHEMBL14031219 | 0.80 | ALDH1A1 (0.49) | KMT2AMEN1ATMMAPTALDH1A1 | |
| SCHEMBL19324162 | 0.80 | ALDH1A1 (0.49) | KMT2AMEN1ATMMAPTALDH1A1 | |
| SCHEMBL13216572 | 0.80 | ALDH1A1 (0.49) | KMT2AMEN1ATMMAPTALDH1A1 | |
| SCHEMBL7306693 | 0.79 | KMT2A (0.36) | KMT2AMEN1ATMMAPTALDH1A1 | |
| SCHEMBL7302241 | 0.79 | KMT2A (0.36) | KMT2AMEN1ATMMAPTALDH1A1 | |
| SCHEMBL7308325 | 0.79 | KMT2A (0.36) | KMT2AMEN1ATMMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140378430-A1 | Heterocyclic Compounds and Methods of Their Use | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2014-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378430-A1 | Heterocyclic Compounds and Methods of Their Use | AGTR2, AGTR1, BDKRB2 | KMT2A 2565/4885MEN1 3729/4885ATM 3191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.